Table 3 Quartiles of change in Hb levels during 12 months and the subsequent 1-year mortality
Hb change range (g/L) | Quartile 1: | Quartile 2: | Quartile 3: | Quartile 4: | p-value |
|---|---|---|---|---|---|
−45 – –10 (n = 58) | −9 – −2 (n = 55) | −1 – +6 (n = 56) | +7 – +28 (n = 51) | (comparing q1 with q4) | |
Hb at baseline in men (g/L) mean ± SD | 134.3 ± 11.0 (n = 22) | 132.6 ± 9.9 (n = 16) | 127.7 ± 14.0 (n = 15) | 112.9 ± 11.3 (n = 12) | p < 0.001 |
Hb at baseline in women (g/L) mean ± SD | 128.2 ± 10.8 (n = 36) | 127.0 ± 13.0 (n = 39) | 123.4 ± 10.9 (n = 41) | 120.5 ± 13.1 (n = 39) | p = 0.007 |
Male sex (%) | 37.9 (n = 22) | 29.1 (n = 16) | 26.8 (n = 15) | 23.5 (n = 12) | P = 0.10 |
Age (years) | 83.4 ± 8.3 (n = 58) | 83.6 ± 6.3 (n = 55) | 83.1 ± 7.3 (n = 56) | 85.7 ± 5.8 (n = 51) | p = 0.10 |
Number of drugs, mean ± SD | 7.2 ± 3.0 (n = 58) | 6.7 ± 2.5 (n = 55) | 6.8 ± 3.1 (n = 56) | 6.7 ± 3.5 (n = 51) | p = 0.47 |
BMI (kg/m2) mean ± SD | 25.5 (±5.1) (n = 58) | 25.6 ± 5.0 (n = 55) | 25.0 ± 4.4 (n = 56) | 24.9 (±4.8) (n = 51) | p = 0.53 |
eGFR (mL/min) | 56.8 ± 16.1 (n = 58) | 55.7 ± 14.3 (n = 55) | 51.9 ± 14.4 (n = 56) | 54.2 ± 15.7 (n = 51) | p = 0.38 |
BNP (ng/L) mean ± SD | 139.4 ± 190.2 (n = 57) | 117.8 ± 166.4 (n = 54) | 159.6 ± 235.8 (n = 55) | 128.6 ± 114.0 (n = 51) | p = 0.72 |
MNA-SF initial result mean ± SD | 10.5 ± 2.3 (n = 58) | 10.9 ± 2.2 (n = 55) | 10.8 ± 2.1 (n = 55) | 10.4 ± 2.8 (n = 51) | p = 0.74 |
MMSE result mean ± SD | 16.2 ± 6.7 (n = 49) | 17.6 ± 6.0 (n = 50) | 17.8 ± 6.5 (n = 49) | 17.9 ± 6.2 (n = 49) | p = 0.20 |
1 year mortality (%) | 36.2 | 18.2 | 17.9 | 17.6 | |
p = 0.032 (q1 vs q2) | p = 0.028 (q1 vs q3) | P = 0.030 (q1 vs q4) |